A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis

Journal of Clinical Gastroenterology

Volumn 24, Issue 4, 1997, Pages 239-244

  Floreani, A ^a,b   Zappala, F ^a   Fries, W ^a   Naccarato, R ^a   Plebani, M ^a   D'Angelo, A ^a   Chiaramonte, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Divisione Gastroenterologia R Farini   (Italy)

Author keywords

ADFR therapy; Bone mineral density; Osteocalcin; Osteodystrophy; Primary biliary cirrhosis

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM CARBONATE; COLESTYRAMINE; ELCATONIN; HYDROXYPROLINE; OSTEOCALCIN; PARATHYROID HORMONE; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OSTEODYSTROPHY; OSTEOPOROSIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL;

BONE DENSITY; CALCITONIN; CALCIUM CARBONATE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LIVER CIRRHOSIS, BILIARY; MIDDLE AGED; OSTEOPOROSIS; PILOT PROJECTS; PROSPECTIVE STUDIES; TIME FACTORS; VITAMIN D;

EID: 0030792592     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-199706000-00012     Document Type: Article

References (24)

1. Hodgson SF, Dickson ER, Wahner HW, et al. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985;103:855-60.
2. Guanabens N, Parés A, Marinoso L, et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990;85:1356-62.
3. Eastell R, Dickson ER, Hodgson SF, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991;14:296-300.
4. Maddrey WC. Bone disease in patients with primary biliary cirrhosis. In: Popper H, Schaffner F, eds. Progress in liver diseases. Philadelphia: WB Saunders Co, 1990:537-54.
5. Hodgson SF, Dickson ER, Eastell R, et al. Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 1993;14:819-27.
6. Rosen H. Primary biliary cirrhosis and bone disease. Hepatology 1995;21:253-5.
7. Floreani A, Chiaramonte M, Giannini S, et al. Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study on calcitonin treatment. J Hepatol 1991;12:217-23.
8. Frost HM. The ADFR concept revisited. Calcif Tissue Int 1984; 36:349-52.
9. Sherlock S. Primary biliary cirrhosis and vanishing bile ducts. In: McIntyre N, Benhamou J-P, Bircher J, et al, eds. Oxford textbook of clinical hepatology. New York: Oxford Medical Publications, 1991:743-50.
10. Scheuer PJ. Primary biliary cirrhosis. Proc R Soc Med 1967;60: 1257-60.
11. Dickson RE, Grambsch PM, Fleming TR, et al. Prognosis in PBC: model for decision making. Hepatology 1989;10:1-7.
12. Reed JS, Meredith SC, Nemchausky BA, et al. Bone disease in primary biliary cirrhosis: reversal of osteomalacia with oral 25-hydroxyvitamin D. Gastroenterology 1989;78:512-7.
13. Matloff DS, Kaplan MM, Neer RM, et al. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982;83:97-102.
14. Epstein O, Kato Y, Dick R, Sherlock S. Vitamin D hydroxyapatite and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis. Am J Clin Nutr 1982;36:426-30.
15. Crippin JS, Jorgensen RA, Dickson ER, Lindor KD. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994;89:47-50.
16. Schreiber AJ, Simon FR. Estrogen-induced cholestasis: clues to pathogenesis and treatment. Hepatology 1983;3:607-13.
17. Guanabens N, Parés A, del Rio L, et al. Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol 1992;15:345-9.
18. Kanis JA. Treatment of symptomatic osteoporosis with fluoride. Am J Med 1993;95(Suppl. 5A):53S-61S.
19. Kanis JA. Clodronate: a new perspective in the treatment of neoplastic bone disease. Bone 1987;8(Suppl):1-86.
20. Canfield RE. Etidronate disodium: a new therapy for hypercalcemia of malignancy. Am J Med 1097;82:1-78.
21. Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-biphosphonate (APD). Lancet 1988;i:143-6.
22. Wolfhagen FHJ, Den Ouden JW, Van Buuren HR, et al. Cyclical etidronate in the prevention of corticosteroid induced bone loss in primary biliary cirrhosis. Gastroenterology 1995;108: A1199.
23. Brown JP, Delmas PD, Malaval L, et al. Serum bone GLA protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984;i:1091-3.
24. Janes CH, Dickson ER, Okazaki R, et al. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995;95: 2581-6.